Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

被引：15
|
作者：
Kater, Arnon P. [1 ]
Christensen, Jacob Haaber [2 ]
Bentzen, Hans Herluf [3 ]
Niemann, Carsten Utoft [4 ]
Hutchings, Martin [4 ]
Chen, Jenny [5 ]
Rios, Marcia [6 ]
Palenski, Tammy [6 ]
Li, Tommy [5 ]
Mato, Anthony R. [7 ]
机构：
[1] Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands
[2] Odense Univ Hosp, Odense, Denmark
[3] Aarhus Univ Hosp, Aarhus, Denmark
[4] Copenhagen Univ Hosp, Rigshospitalet, Copenhagen, Denmark
[5] Genmab, Princeton, NJ USA
[6] AbbVie, N Chicago, IL USA
[7] Mem Sloan Kettering Canc Ctr, Chron Lymphocyt Leukemia Program, New York, NY USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146563
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2627
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable chromosomal abnormalities
    Ferrajoli, Alessandra
    Keating, Michael J.
    Wierda, William G.
    O'Brien, Susan M.
    Padmanabhan, Swaminathan
    Czuczman, Myron S.
    Chanan-Khan, Asher A.
    BLOOD, 2007, 110 (11) : 232A - 232A
  • [42] Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
    Wendtner, Clemens-Martin
    Hillmen, Peter
    Mahadevan, Daruka
    Buehler, Andreas
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David D.
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    Moutouh-de Parseval, Laure
    Hallek, Michael
    Heerema, Nyla A.
    Stilgenbauer, Stephan
    Chanan-Khan, Asher A.
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 417 - 423
  • [43] DIRECT COSTS ASSOCIATED WITH THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RELAPSED OR REFRACTORY IN ARGENTINA
    Godar, M. L.
    Chaves, L.
    Touliet, V
    Kanevsky, D.
    VALUE IN HEALTH, 2018, 21 : S449 - S450
  • [44] Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Fuerstenau, Moritz
    Robrecht, Sandra
    Giza, Adam
    Fink, Anna
    Fischer, Kirsten
    Langerbeins, Petra
    Al-Sawaf, Othman
    Tausch, Eugen
    Schneider, Christof
    Schetelig, Johannes
    Dreger, Peter
    Boettcher, Sebastian
    Kreuzer, Karl-Anton
    Schilhabel, Anke
    Brueggemann, Monika
    Kneba, Michael
    Wendtner, Clemens
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2023, 64 : S18 - S19
  • [45] Lenalidomide active in patients with refractory or relapsed chronic lymphocytic leukemia
    Nature Clinical Practice Oncology, 2007, 4 (3): : 143 - 143
  • [46] Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
    Niemann, Carsten U.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Kater, Arnon P.
    BLOOD, 2021, 137 (08) : 1117 - 1120
  • [47] Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
    Bergmann, Manuela A.
    Goebeler, Maria E.
    Herold, Michael
    Emmerich, Bertold
    Wilhelm, Martin
    Ruelfs, Corinna
    Boening, Lothar
    Hallek, Michael J.
    HAEMATOLOGICA, 2005, 90 (10) : 1357 - 1364
  • [48] A Systematic Literature Review of Utility Estimates for Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
    Yucel, E.
    Hartley, L.
    Bell, J.
    Wolowacz, S.
    Kamgar, F.
    Hawe, E.
    VALUE IN HEALTH, 2022, 25 (12) : S395 - S395
  • [49] BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL
    Tedeschi, A.
    Coscia, M.
    Rossi, D.
    Ricci, F.
    D'Arena, G.
    Orlandi, E.
    Petrizzi, V. Belsito
    Scarfo, L.
    Vitale, C.
    Vismara, E.
    Gaidano, G.
    Morra, E.
    Massaia, M.
    Montillo, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 173 - 173
  • [50] Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)
    Karimi, Yasmin
    Thieblemont, Catherine
    Ghesquieres, Herve
    Cheah, Chan Y.
    Clausen, Michael Roost
    Cunningham, David
    Jurczak, Wojciech
    Linton, Kim M.
    Hutchings, Martin
    Phillips, Tycel Jovelle
    Farooq, Umar
    Kim, Won Seog
    Dinh, Minh H.
    Ghosh, Jagannath
    Pallai, Rajash
    Wielgos-Bonvallet, Monica
    Eskelund, Christian
    Lugtenburg, Pieternella
    Vose, Julie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345